Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLEC | Q15149 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699500 | 1.00 | MAOB (0.65) | MAOBMAOAPTPN1KDM4EMEN1 | |
| SCHEMBL13785972 | 0.91 | MAOB (0.62) | MAOBMAOAPTPN1KDM4EMEN1 | |
| SCHEMBL3824529 | 0.89 | MAOB (0.67) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL4299698 | 0.89 | MAOB (0.67) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL4733332 | 0.88 | MAOB (0.70) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL4733326 | 0.88 | MAOB (0.70) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL7269575 | 0.87 | MAOB (0.60) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL7269573 | 0.87 | MAOB (0.60) | MAOBMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL4696463 | 0.86 | MAOB (0.55) | MAOBMAOAPTPN1KDM4EMEN1 | |
| SCHEMBL4696465 | 0.86 | MAOB (0.55) | MAOBMAOAPTPN1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1954673-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | Sanofi-Aventis Deutschland GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007059871-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | CYP46A1, GPR119, DHCR7 | MAOB 2097/4885MAOA 3122/4885PTPN1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.